A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy. / Wulf, Hans Christian; Al-Chaer, Rami Nabil; Glud, Martin; Philipsen, Peter Alshede; Lerche, Catharina Margrethe.
In: Pharmaceuticals, Vol. 14, No. 5, 433, 05.2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy
AU - Wulf, Hans Christian
AU - Al-Chaer, Rami Nabil
AU - Glud, Martin
AU - Philipsen, Peter Alshede
AU - Lerche, Catharina Margrethe
PY - 2021/5
Y1 - 2021/5
N2 - The high incidence of sunlight-induced human skin cancers reveals a need for more effective photosensitizing agents. In this study, we compared the efficacy of prophylactic photodynamic therapy (PDT) when methylene blue (MB), riboflavin (RF), or methyl aminolevulinate (MAL) were used as photosensitizers. All mice in four groups of female C3.Cg/TifBomTac hairless immunocompetent mice (N = 100) were irradiated with three standard erythema doses of solar-simulated ultraviolet radiation (UVR) thrice weekly. Three groups received 2 x 2 prophylactic PDT treatments (days 45 + 52 and 90 + 97). The PDT treatments consisted of topical administration of 16% MAL, 20% MB, or 20% RF, and subsequent illumination that matched the photosensitizers' absorption spectra. Control mice received no PDT. We recorded when the first, second, and third skin tumors developed. The pattern of tumor development after MB-PDT or RF-PDT was similar to that observed in irradiated control mice (p > 0.05). However, the median times until the first, second, and third skin tumors developed in mice given MAL-PDT were significantly delayed, compared with control mice (256, 265, and 272 vs. 215, 222, and 230 days, respectively; p < 0.001). Only MAL-PDT was an effective prophylactic treatment against UVR-induced skin tumors in hairless mice.
AB - The high incidence of sunlight-induced human skin cancers reveals a need for more effective photosensitizing agents. In this study, we compared the efficacy of prophylactic photodynamic therapy (PDT) when methylene blue (MB), riboflavin (RF), or methyl aminolevulinate (MAL) were used as photosensitizers. All mice in four groups of female C3.Cg/TifBomTac hairless immunocompetent mice (N = 100) were irradiated with three standard erythema doses of solar-simulated ultraviolet radiation (UVR) thrice weekly. Three groups received 2 x 2 prophylactic PDT treatments (days 45 + 52 and 90 + 97). The PDT treatments consisted of topical administration of 16% MAL, 20% MB, or 20% RF, and subsequent illumination that matched the photosensitizers' absorption spectra. Control mice received no PDT. We recorded when the first, second, and third skin tumors developed. The pattern of tumor development after MB-PDT or RF-PDT was similar to that observed in irradiated control mice (p > 0.05). However, the median times until the first, second, and third skin tumors developed in mice given MAL-PDT were significantly delayed, compared with control mice (256, 265, and 272 vs. 215, 222, and 230 days, respectively; p < 0.001). Only MAL-PDT was an effective prophylactic treatment against UVR-induced skin tumors in hairless mice.
KW - PDT
KW - methyl aminolevulinate
KW - methylene blue
KW - riboflavin
KW - photosensitizing agents
KW - ultraviolet radiation
KW - skin tumors
KW - prophylactic treatment
KW - hairless mice
KW - BASAL-CELL CARCINOMA
KW - ACTINIC KERATOSES
KW - DELIVERY
KW - PHOTOCARCINOGENESIS
KW - PHOTOACTIVATION
KW - MULTICENTER
KW - EXPOSURE
KW - SURGERY
U2 - 10.3390/ph14050433
DO - 10.3390/ph14050433
M3 - Journal article
C2 - 34063120
VL - 14
JO - Pharmaceuticals
JF - Pharmaceuticals
SN - 1424-8247
IS - 5
M1 - 433
ER -
ID: 272404503